Labcorp and BML begin 4,000 square-meter expansion at CB Trial Laboratory in Kawagoe City, Japan; lab to focus on gastric cancer and cerebrovascular disease, increase testing capabilities in genomics, anatomic pathology and histology

Sample article from our Health Care Sector

BURLINGTON, North Carolina , May 17, 2023 (press release) –

Advanced technology supports drug development across diseases including cancer and cerebrovascular disease

Labcorp (NYSE: LH), a leading global life sciences company, broke ground on a the expansion project of its CB Trial Laboratory in a ceremony held at the construction site near the BML Research Institute and General Laboratory in Kawagoe City on April 28, 2023. The new facility  enhances the company’s central laboratory presence and drug development capabilities in Japan allowing greater focus on serving the unique healthcare needs affecting people in the region and leveraging technology to expand testing capabilities. Completion of the expanded laboratory is expected by early 2025 and will provide more than 4,000 square meters of additional dedicated space to support global clinical trials managed by Labcorp.

This facility, when complete, will provide Labcorp and BML pharmaceutical and biotechnology clients with enhanced access to central laboratory testing and drug development capabilities. It will deliver a unique set of services to meet the specific needs of the population in Japan, including white glove courier service, and will focus attention on the health conditions that disproportionately affect Japanese citizens, including gastric cancer and cerebrovascular disease. Additionally, Labcorp will provide technological capabilities that will enable BML to significantly expand its specialty testing capabilities in the areas of  genomics, anatomic pathology and histology, as well as the opportunity to partner on emerging companion diagnostics focused on oncology.
Completion of the expanded laboratory is expected by early 2025 and will provide more than 4,000 square meters of additional dedicated space to support global clinical trials managed by Labcorp.

CB Trial Laboratory, which is co-managed by Labcorp and BML, is a leading provider of clinical laboratory testing services in Japan. Under the sponsorship of the construction company, and with the cooperation of Ozaki Shrine, BML and Labcorp executives led the audience in prayer, seeking the safety and security of the construction.

To learn more about Labcorp’s operations in Japan, please click here .

About Labcorp
Labcorp is a leading global life sciences company that provides vital information to help doctors, hospitals, pharmaceutical companies, researchers and patients make clear and confident decisions. Through our unparalleled diagnostics and drug development capabilities, we provide insights and accelerate innovations to improve health and improve lives. With more than 80,000 employees, we serve clients in more than 100 countries. Labcorp (NYSE: LH) reported revenue of $14.9 billion in FY2022. Learn more about us at or follow us on LinkedIn and Twitter @Labcorp .


Labcorp Contacts: Media: Kim Arculeo - 336-436-8263,; Investors: Chas Cook -- 336-436-5076,

* All content is copyrighted by Industry Intelligence, or the original respective author or source. You may not recirculate, redistrubte or publish the analysis and presentation included in the service without Industry Intelligence's prior written consent. Please review our terms of use.

See our dashboard in action - schedule an demo
Dan Rivard
Dan Rivard
- VP Market Development -

We offer built-to-order health care sector coverage for our clients. Contact us for a free consultation.

About Us

We deliver market news & information relevant to your business.

We monitor all your market drivers.

We aggregate, curate, filter and map your specific needs.

We deliver the right information to the right person at the right time.

Our Contacts

1990 S Bundy Dr. Suite #380,
Los Angeles, CA 90025

+1 (310) 553 0008

About Cookies On This Site

We collect data, including through use of cookies and similar technology ("cookies") that enchance the online experience. By clicking "I agree", you agree to our cookies, agree to bound by our Terms of Use, and acknowledge our Privacy Policy. For more information on our data practices and how to exercise your privacy rights, please see our Privacy Policy.